What You Should Know:
– Exo, a health information and devices company, today has announced it has acquired Medo, an FDA-cleared AI platform that makes ultrasound workflow faster, more reliable, and accessible to all.
– By integrating Medo’s AI, Exo enables more caregivers in more settings to capture and interpret medical images – allowing faster and more accurate diagnoses and treatment.
Make Medical Imaging as Easy as Snapping a Smartphone Photo
Ultrasound imaging is complex and requires specialized education and training, limiting the number of caregivers who can use point-of-care ultrasound (POCUS) to improve patient care. Medo’s unique ultrasound AI technology radically lowers the expertise required to diagnose common and critical conditions through automated image capture and interpretation, allowing non-experts to conduct high-quality exams quickly and accurately, improving patient outcomes.
At the core of Medo platform, is the Medo viewer. The viewer helps make sense of ultrasound images by identifying complex anatomic structures and features within the images. This assistance enables the user to make faster and more accurate diagnosis and integrates with other systems such as PACS within the workflow. Medo offerings include:
– Medo Hip: enables a fast and reliable Developmental Hip Dysplasia (DDH) screening option within a clinical setting
– Medo Thyroid: classifies thyroid nodules according to TI-RADS as benign vs. potentially malignant, and organizes the often-complex findings in thyroid ultrasound into a convenient report format.
– Medo Lung: ultrasound images will be efficiently obtained and interpreted by medical personnel caring for patients with lung complications in emergency rooms and intensive care units. Artificial intelligence helps these clinicians detect and interpret ultrasound findings that can be confusing to non-experts, like A-lines, B-lines, sliding pleura and consolidations, to allow for more accurate and objective diagnosis.
“Exo’s powerful hardware and workflow technologies and Medo’s AI will dramatically reduce the challenges that have long held back the widespread adoption of point-of-care ultrasound,” said Dornoosh Zonoobi, CEO of Medo. “The ease of imaging and immediacy of diagnostic information we provide will radically transform medical care, creating a world where caregivers can image the body as easily as snapping a photo on a smartphone.”
Financial details of the acquisition were not disclosed.
